Survival in Biological Technology

OncoGenex Reports Second Quarter 2009 Financial Results

... through 2010, including: - continuing survival follow-up for previously announced phase 2 ... (ASCO) Annual Meeting. Analyses indicated a survival benefit in patients treated with OGX-011 ... compared to docetaxel alone. The median overall survival in patients with advanced metastatic ...

AEterna Zentaris Partner, Keryx, Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial with Perifosine (KRX-0401) for the Treatment of Multiple Myeloma

... myeloma. The primary endpoint is progression-free survival and secondary endpoints include overall response rate, overall survival and safety. Juergen Engel, Ph. D., President ... therapy. The primary endpoint is progression-free survival and secondary endpoints include overall response ...

Sunesis Reports Financial Results for the Second Quarter 2009

... or more. The preliminary median progression free survival (PFS) for each of the three cohorts by increasing ... limited following relapse, and overall long-term survival has not changed significantly over the past 40 years, with five-year survival rates at less than 30 percent. About ...

Monitoring Circulating Tumor Cells With the CellSearch(R) System Can Predict Prognosis in Metastatic Breast Cancer

... count can accurately predict the prognosis and survival in patients with metastatic breast cancer (MBC), ... tomography (FDG-PET/CT), predicted survival in MBC patients on standard therapies. The ... significantly correlate to overall MBC patient survival (p<0.001 for CTCs and p=0.001 for FDG-PET/CT). ...

New Report Just Published: World Prostate Cancer Therapeutics Market Report

... Improved Screening, Diagnosis & Patient survival Rates Trigger Growth II-9 Table 6: Five-Year Prostate Cancer survival Rate in the US by Race, 1975-2002 (includes ... Graph/Chart) II-9 Table 7: Five-Year Cancer survival Rate Among US Males by Type - Prostate and ...

CEL-SCI Corporation Releases Letter to Shareholders

... to mutate - "Constant, random mutation is the survival mechanism of the microbial world. Like all ... has been shown to be non-toxic, to increase survival by 33%, and to eliminate the tumor in 12% of the ... not relevant: We follow overall survival of the patients, the gold standard. The ...

How much is life worth? The $440 billion question

... produce only a relatively short extension of survival is a serious ethical dilemma in the U.S. that ... an additional 1.7 months [the additional overall survival for colorectal cancer patients treated with ... recommend that studies powered to detect a survival advantage of two months or less should test only ...

OncoGenex Pharmaceuticals Completes Amendment to Phase 3 Special Protocol Assessment for Confirming Survival Benefit in Patients Receiving OGX-011 with First-Line Docetaxel for Metastatic Prostate Cancer

... of a previously reviewed Phase 3 trial featuring survival as the primary endpoint. The study population has ... trial for first-line treatment evaluates overall survival benefit for OGX-011 while the trial for ... benefit. Based on the robustness of the OGX-011 survival benefit observed in the randomized Phase 2 trial ...

YM BIOSCIENCES REPORTS DAIICHI-SANKYO ENROLLS FIRST PATIENTS IN PHASE II, FIRST-LINE LUNG CANCER TRIAL WITH NIMOTUZUMAB

... rate, progression-free survival, and the overall survival rate at 12 and 18 months as well as toxicity. ... to provide an important quality of life and survival advantage to patients over radiation alone in the ... CRT regimens improved the overall response rate, survival rate at 30 months, median ...

Phase II Trial Demonstrates Elacytarabine May Increase Survival Threefold in Patients With Late-Stage Leukaemia

... to published clinical data: - Median survival three times longer (5.5 months vs. 1.5 months) ... et al, Cancer 2005;104:547-54). Median overall survival in the elacytarabine study was an impressive ... high rate of disease recurrence. The five-year survival for the most common acute leukaemia type, acute ...

Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer

... Cohorts Have Met or Exceeded the Expected Median survival Time for Recurrent GBM Patients - TORONTO ... all either met or exceeded the expected median survival time of six months for recurrent GBM patients. ... assess overall patient survival, progression free survival and the proportion of patients alive at six ...

Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting

... Shows Promising 7.4 Month Median Progression Free survival in Initial Study Cohort - ORLANDO, Fla. and ... Recent analysis shows the median progression free survival of the patients enrolled in the first part of the ... with the response rates and progression free survival data seen in the initial group of breast cancer ...

PROSTVAC(TM) Data Presented at the ASCO Meeting Demonstrates the Potential for Significant Increases in Life Expectancy in Late-Stage Prostate Cancer

... group had a significantly longer median overall survival by 8.5 months compared to the control group. The ... To see this extent of improvement in overall survival is very encouraging. These phase II data with ... has the potential to extend survival with improved quality of life. PROSTVAC(TM) is ...

Ascenta Therapeutics Announces Presentation of Promising Results From Clinical Trials of AT-101 in Prostate, Brain, and Lung Cancers at 2009 ASCO Annual Meeting

... alive at the time of analysis. Progression-free survival (PFS) in these patients ranged from 8 to 13 ... Determination of the impact of AT-101 on overall survival (OS), the primary endpoint, is ongoing. ... also demonstrated a 33 percent increase in median survival and a 34 percent increase in ...

NIMOTUZUMAB DEMONSTRATES EFFICACY IN RANDOMIZED HEAD & NECK CANCER STUDY WITHOUT THE TOXICITIES ASSOCIATED WITH OTHER EGFR DRUGS

... regimens improved the overall response rate, survival rate at 30 months, median progression-free survival and median overall survival. A combined group ... demonstrated a significant difference in overall survival (p=0.0018) favoring nimotuzumab. The addition of ...

OncoGenex Pharmaceuticals Announces OGX-011 Treatment Provides Survival Benefit in Randomized Phase 2 Trial in Advanced Metastatic Prostate Cancer

... (ASCO) Annual Meeting. Analyses indicated a survival benefit in patients treated with OGX-011 in ... prostate cancer: 1) The median overall survival in patients with advanced metastatic ... docetaxel alone -- a 6.9 month observed survival advantage for the OGX-011 arm. 2) The ...

OncoGenex Pharmaceuticals Announces OGX-427 Treatment Demonstrates Safety, Evidence of Declines in Circulating Tumor Cells and Reductions in Tumor Markers in a Phase 1 Cancer Trial

... including statements concerning the potential survival benefit of OGX-011, anticipated clinical ... the possibility that any benefit in patient survival will not be maintained or will become less substantial as patient survival follow up continues, risks that clinical trials ...

OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427

... in December 2008, the preliminary median overall survival in patients with advanced prostate cancer who ... a measure used to determine the difference in survival between treatment groups, was 0.60, representing ... (HR=0.54; p=0.04). The abstract represents survival data as of November 2008. ...

Boston Scientific Announces Company Schedule for Heart Rhythm Society Scientific Sessions

... Thursday, May 14 survival after ICD and CRT-D Implant. Leslie Saxon, M.D., will present data on survival rates from the ALTITUDE Clinical Program. The ... a press release at this time. Extended survival Analysis from MADIT II. Ilan Goldenberg, M.D., ...

OncoGenex Reports First Quarter Financial Results

... Officer of OncoGenex. "The final comprehensive survival analysis from the randomized Phase 2 clinical ... The oral presentation will update the preliminary survival data that was released in December 2008 that ... of advanced prostate cancer, featuring either survival or pain palliation as the primary endpoint. We ...

Independent Data Monitoring Committee Supports Continuation of Picoplatin Phase 3 SPEAR Registration Trial in Small Cell Lung Cancer

... to show a 33 percent reduction in risk in overall survival for the treatment arm compared to BSC alone ... treated with picoplatin showed a median overall survival of 27 weeks(1). Historical data indicates that ... with recurrent SCLC have a median overall survival of 14 weeks(2). Based on patient enrollment data, ...

Medarex Announces Presentations at Annual Meeting of the American Society of Clinical Oncology

... - Updated survival and Biomarker Data for Ipilimumab to be Presented ... events (irAEs) and disease control or overall survival in patients (pts) with advanced melanoma treated ... 2009. "Long-term survival in patients (pts) with advanced melanoma treated ...

OncoGenex Receives Confirmation from FDA on the Design of a Second Phase 3 Trial Evaluating OGX-011 for the Treatment of Advanced Prostate Cancer

... "One trial design evaluates overall survival benefit while the second trial design evaluates ... "The FDA's acknowledgement of pain in addition to survival as key endpoints for market approval supports the ... endpoint for FDA approval. Our focus remains on survival and pain palliation, both endpoints that FDA has ...

PROVENGE Significantly Prolongs Survival in Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study

... Statistically Significant Improvement in Overall survival - - First Active Immunotherapy for Cancer to Prolong survival - - Full Data to be Presented at Plenary ... met its primary endpoint of improving overall survival compared to a placebo control. The magnitude of ...

Oncolytics Biotech(R) Inc. Collaborators Present Positive Head and Neck Results in Phase I/II Combination REOLYSIN(R) and Paclitaxel/Carboplatin Trial

... initial treatment, the median progression-free survival (PFS) is currently six months, while the overall survival is currently seven months. The literature ... a PFS of approximately two months and a median survival ranging from 4.5 to 6.5 months. The ...

OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009

... "We released Phase 2 clinical data showing a survival benefit in patients treated with OGX-011 and are ... Key Objectives for 2009 - Report final survival data with additional results from the Phase 2 ... particularly regarding the benefits of overall survival and pain palliation for the treatment of CRPC," ...

BN ImmunoTherapeutics Reports Further Data on PROSTVAC(TM)

... 210) Study title: "Comparing the Overall survival of Metastatic Castration-Resistant Prostate ... (NCI) conducted study comparing the overall survival in patients with advanced prostate cancer, where ... The study compared the predicted overall survival (as determined by the Halabi score), with the ...

OncoGenex Provides Update on Two-Year Survival Data from Ongoing Phase 1/2 Clinical Trial of OGX-011 in Non-Small Cell Lung Cancer

... (NASDAQ: OGXI ) today announced the two-year survival rate from a Phase 1/2 clinical trial of OGX-011 ... OncoGenex has previously reported a mature median survival of 14.1 months and a one-year survival rate of 54%. For comparison, published studies ...

InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF

... of categorical change in FVC and progression-free survival (PFS). The primary endpoint was not met in ... comes first 2. Progression-free survival defined as time to the first occurrence ... and symptoms increase in severity. The median survival time from diagnosis is two to five years, with a ...

Transplant Program Tops in Expected One-Year Survival Rate

... consistently outperformed the expected one-year survival rate for unrelated donor transplants, ... Blood and Marrow Transplant Registry examined the survival rates of 8,847 transplants performed to treat ... their families and the public with comparative survival rates among the transplant centers in the NMDP ...

REXIN-G Shrinks Metastatic Tumors and Triples Survival Time in Chemotherapy-Resistant Pancreatic Cancer: Analysis of a U.S. Phase I/II Clinical Trial (Proceedings of ASCO GI Symposium 2009)

... Importantly, Rexin-G improved patient survival in a dose-dependent manner: At Dose Level I, median progression-free survival was 3 months, and median over-all survival was 5 months, while at Dose Level II, median ...

Sunesis Pharmaceuticals Provides Year-End Clinical Update on Voreloxin

... or partial response. Median progression free survival is 82 days. All patients at this dose level are ... limited following relapse and overall long-term survival has not changed significantly over the past 40 years, with five-year survival rates at less than 30 percent. About ...

YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER

... the benefits of radiotherapy and increase survival and quality of life while avoiding the toxic ... Phase II study will evaluate nimotuzumab's survival benefit in combination with external radiotherapy ... to provide an important quality of life and survival advantage to patients over radiation alone in the ...

Kidneys for Transplant Function Earlier and Last Longer When Preserved in a Machine Compared to the Traditional Box of Ice

... have an increased risk of rejection (3) and survival of the kidney graft may be compromised. This in ... have an increased risk of rejection and survival of the transplanted kidney may be inferior.(2) ... Secondary endpoints included: patient and graft survival up to 12 months after transplantation, duration ...

OGX-011 Shows Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study

... First-line trial currently shows median overall survival of 27.5 months for OGX-011 in combination ... and prednisone and a 16.9 months overall survival for docetaxel and prednisone alone. Achievement of survival benefit milestone results in release of ...

Cynvec LLC(SM) Appoints Former Johnson & Johnson Executive Frank D. Stonebanks as President and Chief Executive Officer

... and has shown statistically significant survival rates in both ovarian and pancreatic cancer tumor ... spread of tumors, but also significantly enhance survival in preclinical studies. I look forward to working ... and has shown statistically significant survival rates in both ovarian and pancreatic cancer ...

Bradmer sponsors physician panel to raise awareness of brain cancer treatments

... (temozolomide), extended average overall patient survival from 53 to 64 weeks. About the GLASS-ART ... name from its description: GBM Locoregional Agent survival Study - Antitenascin Radiolabeled antibody Therapy Trial. The study is designed to determine the survival benefit derived from, and safety of, adding ...

OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011

... 3 registration trial of OGX-011 targeting overall survival as a primary endpoint for the treatment of HRPC," ... designed to block production of clusterin, a cell survival protein that is over-produced in several cancer ... progression, treatment resistance and shorter survival duration. OGX-011 is being evaluated in five ...

Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice

... product ENB-0040, significantly increases survival and prevents bone hypomineralization associated ... of ENB-0040 was shown to significantly improve survival and prevent skeletal and dental manifestations of ... administration of ENB-0040 significantly improved survival and prevented the skeletal and dental ...

Positive SPA Reply From the FDA for TopoTarget's Pivotal Trial With Belinostat in PTCL

... time to progression (TTP), progression-free survival (PFS), one-year progression-free rate, one-year survival rate and overall survival (OS). Today's news does not change TopoTarget's ... treatment with cytotoxic agents, and 5-year survival is less than 30%. T-cell Non Hodkins Lymphomas, ...